Burrage Capital Management as of March 31, 2021
Portfolio Holdings for Burrage Capital Management
Burrage Capital Management holds 27 positions in its portfolio as reported in the March 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Protalix Biotherapeutics (PLX) | 7.7 | $9.5M | 2.1M | 4.46 | |
| BioCryst Pharmaceuticals (BCRX) | 7.1 | $8.8M | 865k | 10.17 | |
| Mei Pharma | 6.5 | $8.0M | 2.3M | 3.43 | |
| Ptc Therapeutics I (PTCT) | 6.2 | $7.6M | 160k | 47.35 | |
| NeoGenomics (NEO) | 5.8 | $7.1M | 148k | 48.23 | |
| Essa Pharma Com New (EPIX) | 5.6 | $6.9M | 237k | 29.05 | |
| Turning Point Therapeutics I | 5.5 | $6.8M | 72k | 94.59 | |
| Cytokinetics (CYTK) | 4.6 | $5.7M | 245k | 23.26 | |
| Intellia Therapeutics (NTLA) | 4.1 | $5.1M | 64k | 80.26 | |
| Harmony Biosciences Hldgs In (HRMY) | 4.0 | $5.0M | 150k | 33.04 | |
| Epizyme | 4.0 | $4.9M | 565k | 8.71 | |
| Crinetics Pharmaceuticals In (CRNX) | 3.4 | $4.2M | 272k | 15.28 | |
| Mirum Pharmaceuticals (MIRM) | 3.3 | $4.1M | 206k | 19.82 | |
| Cara Therapeutics (CARA) | 3.2 | $3.9M | 180k | 21.71 | |
| Fulcrum Therapeutics (FULC) | 3.1 | $3.8M | 320k | 11.78 | |
| Tricida | 2.8 | $3.5M | 659k | 5.29 | |
| Apellis Pharmaceuticals (APLS) | 2.8 | $3.5M | 81k | 42.91 | |
| Y Mabs Therapeutics (YMAB) | 2.8 | $3.5M | 115k | 30.24 | |
| Inozyme Pharma (INZY) | 2.7 | $3.4M | 170k | 19.80 | |
| Avrobio Ord (AVRO) | 2.5 | $3.1M | 245k | 12.69 | |
| Adc Therapeutics Sa SHS (ADCT) | 2.5 | $3.0M | 125k | 24.41 | |
| Geron Corporation (GERN) | 2.4 | $3.0M | 1.9M | 1.58 | |
| G1 Therapeutics (GTHX) | 2.3 | $2.8M | 118k | 24.06 | |
| Merus N V (MRUS) | 2.2 | $2.7M | 131k | 20.89 | |
| Black Diamond Therapeutics (BDTX) | 2.2 | $2.7M | 110k | 24.26 | |
| Turning Point Therapeutics I Put | 0.7 | $861k | 700.00 | 1230.00 | |
| Intellia Therapeutics Put | 0.0 | $46k | 630.00 | 73.02 |
